CGS 15435

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CGS 15435 是一种有效的血栓烷 (TxA2) 合成酶抑制剂，IC50 为 1 nM， 比作用于环氧合酶，PGI2 合成酶和脂氧合酶的选择性高 100000 倍。

CGS 15435, a potent thromboxane (TxA2) synthetase inhibitor with an IC50 of 1 nM, has a selectivity for Tx synthetase 100000-fold greater than that for cyclooxygenase, PGI2 synthetase and lipoxygenase enzymes.

CGS 15435 is a highly specific Tx synthetase inhibitor. CGS 15435 is only weakly effective as an inhibitor of PGE2 (Cyclooxygenase, IC50=1200 μM), prostacyclin (PGI2 synthetase, IC50=90 μM) or 5-Lipoxygenase (IC50=60 μM) product formation.

CGS 15435 has a long duration of action, since the increases in the plasma levels of TxB2 are prevented even at 24 h after CGS 15435 administration. CGS 15435 significantly inhibits TxB2 formation 4, 6, 12 and 24 h after dosing. Administration of CGS 15435 0.25 or 24 h prior to Arachidonic acid (AA) produced no increase in TxB2 in the surviving animals (4/4 and 5/6, respectively). The final TxB2 levels in the CGS15435A (0.25 and 24 h pretreatment) groups are significantly lower (P<0.05) than those seen in the AA or the Dazoxiben (2 h pretreatment) groups.

——

Metabolic Enzyme/Protease

PPAR

PPAR

——

——

95853-92-2

356.85

C20H21ClN2O2

>98% (HPLC)

——

C(CCCCC(O)=O)C1=C(N(C)C=2C1=CC(Cl)=CC2)C=3C=CC=NC3

——

(-20℃)

With Ice Pack

≥ 2 years